Advertisement

Search Results

Advertisement



Your search for The ASCO Post matches 17639 pages

Showing 16901 - 16950


gynecologic cancers
gynecologic cancers

ESMO 2014: Adding Cediranib to Chemotherapy Improves Progression-Free Survival in Metastatic or Recurrent Cervical Cancer

For patients with recurrent or metastatic cervical cancer, adding the experimental drug cediranib to standard chemotherapy improved tumor shrinkage and resulted in a modest improvement in progression-free survival, researchers reported at the ESMO 2014 Congress in Madrid (Abstract LBA25_PR). In...

cns cancers
lung cancer
gynecologic cancers

Aldoxorubicin Receives FDA Orphan Drug Designations for Glioblastoma, Small Cell Lung Cancer, and Ovarian Cancer

The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designations to aldoxorubicin in three indications: glioblastoma multiforme, small cell lung cancer, and ovarian cancer. Aldoxorubicin combines doxorubicin with a novel single-molecule linker that binds directly and...

lung cancer
issues in oncology

Screening for and Treating Early-Stage Lung Cancer Is Less Costly Than Treating Late-Stage Disease

A new study found that the average cost to screen high-risk individuals for lung cancer with low-dose computed tomography (CT) plus the average cost of curative-intent treatment is lower than the average cost to treat advanced-stage lung cancer, which quite rarely results in a cure. The findings by ...

cns cancers

FDA Grants Orphan Drug Designation to Bivalent Vaccine for Neuroblastoma

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to MabVax Therapeutics’ vaccine for the treatment of relapsed or recurrent high-risk neuroblastoma in remission or with limited residual disease after best available treatment. The bivalent vaccine is intended to...

hematologic malignancies

Preclinical Study Identifies Potential Drug Combination for Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia

Combining the molecular targeted drug ibrutinib (Imbruvica) with the investigational anticancer agent ABT-199 may improve outcomes for patients with mantle cell lymphoma and chronic lymphocytic leukemia (CLL), according to preclinical data presented at the American Association for Cancer Research...

solid tumors

Second-Line Ramucirumab Plus Paclitaxel Improves Overall Survival in Patients With Advanced Gastric Cancer

The addition of the monoclonal antibody VEGFR-2 antagonist ramucirumab (Cyramza) to paclitaxel led to a statistically significant improvement in median overall survival in patients with advanced gastric cancer or gastroesophageal junction adenocarcinoma in a phase III trial, reported Wilke et al in ...

head and neck cancer

Lymphatic Mapping Agent Receives Orphan Drug Designation for Head and Neck Cancers

Navidea Biopharmaceuticals, Inc, recently announced that technetium 99m tilmanocept (Lymphoseek Injection) has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for use in sentinel lymph node detection in patients with cancer of the head and neck. The designation...

lung cancer

ASTRO: Analysis Finds Select Group of Stage IV Lung Cancer Patient Population Achieves Long-Term Survival After Aggressive Treatment

A large, international analysis of patients with stage IV non–small cell lung cancer (NSCLC) indicates that a patient’s overall survival rate can be related to factors including the timing of when metastases develop and lymph node involvement, and that aggressive treatment for low-risk...

lung cancer

ASTRO: Good Primary Tumor Control, Positive 5-Year Survival Rates for Lung Cancer Patients Who Receive Stereotactic Body Radiation Therapy

Patients with inoperable, early-stage lung cancer who receive stereotactic body radiation therapy have a 5-year survival rate of 40%, according to long-term results presented at the American Society for Radiation Oncology’s (ASTRO) 56th Annual Meeting (Abstract 56). Such a positive survival...

prostate cancer

ASTRO: Long-Term Androgen-Deprivation Therapy Plus High-Dose Radiation Therapy Improves Biochemical Control and Survival Rates in Prostate Cancer

Prostate cancer patients who receive high-dose radiation therapy followed by a longer period of androgen-deprivation therapy have higher 5-year biochemical disease–free survival and overall survival rates compared to patients who receive high-dose radiation therapy and a shorter duration of...

breast cancer

ASTRO: Radiation Therapy Does Not Increase Risk of Lymphedema in Node-Negative Breast Cancer

A secondary analysis of the National Surgical Adjuvant Breast and Bowel Project B-32 trial indicates that radiation therapy does not increase the incidence of lymphedema in patients with node-negative breast cancer, according to research presented at the American Society for Radiation...

issues in oncology
gastroesophageal cancer

ASTRO: Pretreatment Serum Levels of VEGF-A and TGF-β1 Predictive of Outcomes in Esophageal Cancer

Serum levels of VEGF-A and TGF-β1 may be helpful in tailoring neoadjuvant treatment regimens for patients with esophageal squamous cell carcinoma, according to research presented at the American Society for Radiation Oncology’s (ASTRO) 56th Annual Meeting (Abstract 10). Results of...

gastroesophageal cancer

ASTRO: Radiation Therapy Alone vs Chemoradiotherapy for Reducing Dysphagia in Advanced Esophageal Cancer

Radiation therapy alone is as effective in decreasing swallowing complications experienced by advanced esophageal cancer patients as radiation therapy combined with chemotherapy, thus allowing patients to forgo chemotherapy, according to research presented at the American Society for Radiation...

prostate cancer

ASTRO: Shorter Course of Androgen-Deprivation Therapy Yields Improved Quality of Life for High-Risk Prostate Cancer Patients

Patients with high-risk prostate cancer who received radiation therapy and an 18-month course of androgen-deprivation therapy recovered a normal testosterone level in a shorter amount of time compared to those who received a 36-month course of androgen-deprivation therapy. The shorter course of...

lymphoma

ASTRO: Radiation Therapy Improves Survival in Patients With Early-Stage Hodgkin Lymphoma

Patients with stage I and II Hodgkin lymphoma who received consolidated radiation experienced improved 10-year survival rates, according to research presented at the American Society for Radiation Oncology (ASTRO) 56th Annual Meeting (Abstract CT-08). The 10-year survival rate for patients who...

leukemia

Genomic Analysis Reveals That a High-Risk Leukemia Subtype Becomes More Common With Age

More than one-quarter of young adults with the most common form of acute lymphoblastic leukemia have a high-risk subtype with a poor prognosis and may benefit from drugs widely used to treat other types of leukemia that are more common in adults, according to multi-institutional research led by St. ...

prostate cancer

FDA Approves New Indication for Enzalutamide in Metastatic Castration-Resistant Prostate Cancer

The U.S. Food and Drug Administration (FDA) has approved a new indication for the use of enzalutamide (Xtandi) capsules to treat patients with metastatic castration-resistant prostate cancer. The new indication is for men with metastatic castration-resistant prostate cancer who have not received...

gynecologic cancers

Radiation Therapy With Concurrent Chemotherapy After Surgery Is an Effective Treatment for High-Risk Endometrial Cancer

Radiation therapy with concurrent paclitaxel chemotherapy following surgery is an effective treatment for high-risk endometrial cancer, according to a study reported by Cho et al in the International Journal of Radiation Oncology • Biology • Physics   Endometrial...

prostate cancer

ASCO and Cancer Care Ontario Release Clinical Practice Guideline for Systemic Therapy in Men With Metastatic Castration-Resistant Prostate Cancer

The ASCO Clinical Practice Guidelines Committee and the Cancer Care Ontario (CCO) program in evidence-based care have released a clinical practice guideline on systemic therapy in men with metastatic castration-resistant prostate cancer. The guideline is reported by Basch et al in the Journal of...

hepatobiliary cancer

Phase II Trial Shows Overall Survival Benefit With VT-122 Plus Sorafenib in Advanced Hepatocellular Carcinoma

The investigational agent VT-122 appeared to benefit survival when combined with sorafenib (Nexavar) in patients with advanced hepatocellular carcinoma, according to data presented at the 8th Annual International Liver Cancer Association Conference in Kyoto, Japan. Researchers reported an 11-month...

breast cancer

Breast-Conserving Therapy Shows Survival Benefit Over Mastectomy in Patients With Early-Stage Hormone Receptor–Positive Disease

When factoring in what is now known about breast cancer biology and heterogeneity, breast-conserving therapy may offer a greater survival benefit over mastectomy to women with early-stage, hormone receptor–positive disease, according to research from The University of Texas MD Anderson Cancer ...

breast cancer

Once-Weekly Breast Irradiation Following Lumpectomy Results in Better Compliance, Lower Costs, and Comparable Cosmetic Outcomes vs Daily Treatment

An experimental regimen of once-weekly breast irradiation following lumpectomy provides more convenience to patients at a lower cost, results in better completion rates of prescribed radiation treatment, and produces cosmetic outcomes comparable to the current standard of daily radiation. These...

breast cancer
issues in oncology

Disparities Persist in Early-Stage Breast Cancer Treatment

Despite its acceptance as standard of care for early-stage breast cancer almost 25 years ago, barriers still exist that preclude patients from receiving breast-conserving therapy, with some still opting for a mastectomy, according to research from The University of Texas MD Anderson Cancer Center....

breast cancer

Novel Immunotherapy Vaccine Decreases Recurrence in HER2-Positive Breast Cancer Patients

A new breast cancer vaccine candidate, GP2, provides further evidence of the potential of immunotherapy in preventing disease recurrence. This is especially the case for high-risk patients when it is combined with a powerful immunotherapy drug. These findings were presented at the 2014 Breast...

skin cancer

FDA Approves Pembrolizumab for Advanced Melanoma

The U.S. Food and Drug Administration (FDA) today granted accelerated approval to the anti–PD-1 antibody pembrolizumab (Keytruda) for the treatment of patients with advanced or unresectable melanoma who are no longer responding to other drugs. Pembrolizumab is intended for use following...

breast cancer

Survey Reveals Factors Influencing Women’s Consideration of Contralateral Prophylactic Mastectomy

A survey of 150 women newly diagnosed with breast cancer provides new insight into factors that influence women’s decisions to undergo contralateral prophylactic mastectomy. This is one of the first studies to look at women’s breast surgery preferences prospectively, before they undergo ...

breast cancer

Breast Cancer Surgery and Reconstruction Complications Are Rare, but Risk of Some Complications Higher With Bilateral vs Unilateral Mastectomy

A new analysis of 30-day post-surgery complications among more than 18,000 women with breast cancer undergoing bilateral and unilateral mastectomy with breast reconstruction found that complications were generally rare for either type of surgery, with an overall rate of complications of 5.3%....

breast cancer
issues in oncology

Family Physician–Signed Reminder Letters Improve Return Rates for Women Overdue for Screening Mammography

A large study conducted through the BC Cancer Agency in British Columbia, Canada, reports that adding family physician–signed reminder letters to the standard schedule of postcard reminders substantially improves return rates for screening among women who are overdue for such screening. In a...

cns cancers

FDA Grants Priority Review to Lanreotide Injection for Gastroenteropancreatic Neuroendocrine Tumors

The U.S. Food and Drug Administration (FDA) has accepted and granted priority review to Ipsen’s supplemental New Drug Application (sNDA) for the somatostatin analog lanreotide (Somatuline Depot) 120 mg injection in the treatment of gastroenteropancreatic neuroendocrine tumors. The FDA...

breast cancer

Response to Neoadjuvant Chemotherapy and Tumor Subtype Are Strong Predictors of Locoregional Breast Cancer Recurrence

An analysis of data from 12 large clinical trials found that the cancer’s pathologic response to neoadjuvant chemotherapy and tumor subtype are strong predictors of locoregional breast cancer recurrence. According to the researchers, the study showed that these two predictors may be more...

breast cancer
issues in oncology

Angelina Jolie’s Story May Have Helped Double BRCA Testing Rates at a Canadian Cancer Center

A retrospective review of records at an academic cancer center in Ontario, Canada, found that referrals for genetic counseling and the rates of genetic testing performed almost doubled over the 6-month period after Angelina Jolie announced she underwent a preventive double mastectomy because she...

Circulating Tumor Cell Clusters More Likely to Cause Metastasis Than Single Cells

Circulating tumor cell clusters—clumps of from 2 to 50 tumor cells that break off a primary tumor and are carried through the bloodstream—appear to be much more likely to cause metastasis than are single circulating tumor cells, according to a study from investigators at the...

colorectal cancer

Addition of Irinotecan to Standard Chemotherapy Improves Survival in a Subset of Stage III Colon Cancer Patients

A subset of patients with stage III colon cancer had improved survival rates when treated with irinotecan-based therapy, according to a new study in Gastroenterology. When added to the standard chemotherapy treatment—fluorouracil [5-FU] and leucovorin—adjuvant irinotecan therapy...

prostate cancer
issues in oncology

RNA Sequencing Could Help Doctors Tailor Unique Prostate Cancer Treatment Programs

Sequencing RNA, not just DNA, could help doctors predict how prostate cancer tumors will respond to treatment, according to research published in the journal Genome Biology. Because a tumor’s RNA shows the real-time changes a treatment is causing, the authors believe that this could be a...

leukemia

Study Provides Blueprint for Next Generation of Chronic Myeloid Leukemia Treatment

Researchers at Huntsman Cancer Institute (HCI) at the University of Utah have identified and characterized mutated forms of the gene that encodes BCR-ABL, the unregulated enzyme driving chronic myeloid leukemia (CML). The findings by Zabriskie et al were published in Cancer Cell. Although tyrosine ...

colorectal cancer

Study Shows Curcumin Blocks the Metastasis of Colon Cancer by a Novel Mechanism

A team of researchers led by the University of Arizona Steele Children’s Research Center discovered that curcumin—the bioactive molecule derived from the spice turmeric—blocks the protein cortactin in colon cancer. Cortactin, a protein essential for cell movement, is frequently...

prostate cancer

Study Finds Widespread Adoption of Robot-Assisted Prostatectomy in United States

A new study reveals that the United States has experienced widespread adoption of robot-assisted prostatectomy to treat prostate cancer in recent years. The findings, reported by Chang et al in BJU International, also showed that although such surgeries are more expensive than traditional...

lung cancer
issues in oncology

High Concordance Between EGFR Mutations From Circulating-Free Tumor DNA and Tumor Tissue in NSCLC

Epidermal growth factor receptor (EGFR) mutations found in the circulating-free tumor DNA from the plasma of advanced non–small cell lung cancer (NSCLC) patients correlates well with the EGFR mutations from patient-matched tumor tissue DNA, according to new data reported by Douillard et...

cns cancers

Early Study Identifies Tumor-Suppressor Gene, Potential Therapy for Medulloblastoma

An international, multi-institutional research group led by scientists at the Cancer and Blood Diseases Institute (CBDI) at Cincinnati Children’s Hospital Medical Center has identified a novel molecular pathway that causes an aggressive form of medulloblastoma, The study, reported by He et al ...

lymphoma
survivorship

Study Estimates Risk of Premature Menopause After Treatment for Hodgkin Lymphoma

Previous research has suggested that women with Hodgkin lymphoma who receive certain types of chemotherapy or radiotherapy are at increased risk of future infertility, but there was insufficient information to provide patients with detailed advice. In a study published in the Journal of the...

kidney cancer
issues in oncology

Genomic Sequencing Reveals Unique Genetic Alterations in Chromophobe Renal Cell Carcinoma

An international scientific collaboration led by Baylor College of Medicine as part of The Cancer Genome Atlas initiative has revealed clues about genetic alterations that may contribute to a rare form of kidney cancer. The study, which describes the landscape of somatic genomic alterations of...

prostate cancer
issues in oncology

Swedish Study Reports Increasing Rates of Severe Infection Requiring Hospitalization After Prostate Biopsy

Transrectal ultrasound guided biopsy is the standard for detecting prostate cancer, but international reports have suggested that the risks associated with the procedure are increasing. In a new nationwide population-based study reported in The Journal of Urology, Swedish researchers found that 6%...

lung cancer

Previous Pulmonary Disease May Be Linked to Increased Lung Cancer Risk in Large Study

Links between a number of common respiratory diseases and an increased risk of developing lung cancer have been found in a large pooled analysis of seven studies involving more than 25,000 individuals. The findings by Denholm et al were published in the American Journal of Respiratory and Critical...

gynecologic cancers

FDA Approves Bevacizumab for Aggressive and Late-Stage Cervical Cancer

The U.S. Food and Drug Administration (FDA) has approved the antiangiogenic agent bevacizumab (Avastin) for the treatment of persistent, recurrent, or metastatic cervical cancer. The new indication is approved for use in combination with paclitaxel and cisplatin or paclitaxel and topotecan. The FDA ...

issues in oncology
gynecologic cancers

Researchers Identify Priority Targets for Immunotherapy in Epithelial Ovarian Cancer

Researchers at Roswell Park Cancer Institute (RPCI) have found that the expression pattern of a unique class of tumor-associated antigens, known as the MAGE cancer-testis antigens (CTAs), correlates with clinical outcome in epithelial ovarian cancer. Based on their findings, the researchers have...

hepatobiliary cancer
issues in oncology

Scientists Pinpoint Gene Likely to Promote Childhood Cancers

Researchers at the Children’s Medical Center Research Institute at UT Southwestern (CRI) have identified a gene that contributes to the development of several childhood cancers, in a study conducted in mouse models. If the findings prove to be applicable to humans, the research could...

issues in oncology
prostate cancer

Prostate Cancer Prevention Trial Identifies Men Most Likely to Undergo Challenging Study Procedures

Healthy men participating in the Prostate Cancer Prevention Trial who actively participate in all steps of the clinical trial are most likely to undergo a biopsy, according to a study by Gritz et al published in Cancer Epidemiology, Biomarkers & Prevention. The Prostate Cancer Prevention Trial, ...

lung cancer

U.S. Lung Cancer Rates Vary by Subtype, Sex, Race/Ethnicity, and Age

A new analysis confirms that U.S. lung cancer rates are declining overall, but it also uncovers previously unrecognized trends related to cancer subtype, sex, race/ethnicity, and age. Published early online in Cancer, the findings provide a more accurate picture of the state of lung cancer in the...

colorectal cancer
issues in oncology

FDA Approves First Noninvasive DNA Screening Test for Colorectal Cancer

The U.S. Food and Drug Administration (FDA) today approved Cologuard, the first stool-based colorectal screening test that detects the presence of red blood cells and DNA mutations that may indicate the presence of certain kinds of abnormal growths that may be cancers such as colon cancer or...

multiple myeloma

FDA Approves Bortezomib Retreatment in Patients With Multiple Myeloma

The U.S. Food and Drug Administration has approved bortezomib (Velcade) for the retreatment of adult patients with multiple myeloma who had previously responded to bortezomib therapy and relapsed at least 6 months following completion of prior bortezomib treatment. The labeling update includes...

Advertisement

Advertisement




Advertisement